0P5I Stock Chart & Stats
€0.07
-€0.01(-6.06%)
At close: 4:00 PM EST
€0.07
-€0.01(-6.06%)
Day’s Range― - ―
52-Week Range€0.07 - €0.23
Previous CloseN/A
Volume1.68K
Average Volume (3M)1.12K
Market Cap
€18.82M
Enterprise Value€39.82M
Total Cash (Recent Filing)€2.35M
Total Debt (Recent Filing)€11.83M
Price to Earnings (P/E)1.5
Beta2.19
Next Earnings
Apr 22, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.06
Shares Outstanding195,260,220
10 Day Avg. Volume1,044
30 Day Avg. Volume1,124
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-2.65
Price to Sales (P/S)1.55
P/FCF Ratio-3.24
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.01
Revenue Forecast (FY)€7.75M
Bulls Say, Bears Say
Bulls Say
Revenue ReboundThe 2025 revenue rebound shows that demand can recover materially after a weak period, supporting renewed commercial traction for Cellvizio. If sustained, higher revenue could improve operating leverage and provide a stronger base for expanding the installed platform and consumables business.
Strong Gross MarginA consistently high gross margin indicates that the company retains substantial value from each unit of revenue generated by its technology and related products. This provides potential operating leverage and could support improved profitability if revenue growth is maintained and fixed costs are controlled.
Debt ReductionThe substantial reduction in debt is a meaningful deleveraging step that can lower financing pressure and improve financial flexibility relative to the prior year. Although the balance sheet remains stressed, less debt may reduce refinancing demands and leave more resources for ongoing operations.
Bears Say
Deep Operating LossesThe deeply negative operating margin shows that the core business is not yet covering its operating cost base, even with strong gross margins and recovering revenue. This limits the durability of reported earnings and means further growth may not translate into sustainable operating profitability.
Persistent Cash BurnPersistent negative operating and free cash flow indicate that the business is not funding operations internally. Continued cash burn can increase reliance on external funding or balance-sheet actions, limiting investment flexibility and weakening resilience if revenue recovery loses momentum.
Negative EquityNegative shareholders’ equity reflects accumulated deficits and leaves the company with limited balance-sheet capacity to absorb setbacks. Even after debt reduction, the weak equity base keeps solvency and refinancing risks elevated and constrains the company’s ability to fund growth internally.
MAUNA KEA TECHNOLOGIES News
0P5I FAQ
What was MAUNA KEA TECHNOLOGIES’s price range in the past 12 months?
MAUNA KEA TECHNOLOGIES lowest share price was €0.07 and its highest was €0.23 in the past 12 months.
What is MAUNA KEA TECHNOLOGIES’s market cap?
MAUNA KEA TECHNOLOGIES’s market cap is €18.82M.
When is MAUNA KEA TECHNOLOGIES’s upcoming earnings report date?
MAUNA KEA TECHNOLOGIES’s upcoming earnings report date is Apr 22, 2027 which is in 174 days.
How were MAUNA KEA TECHNOLOGIES’s earnings last quarter?
MAUNA KEA TECHNOLOGIES released its earnings results on Oct 08, 2026. The company reported -€0.026 earnings per share for the quarter.
Is MAUNA KEA TECHNOLOGIES overvalued?
According to Wall Street analysts MAUNA KEA TECHNOLOGIES’s price is currently Overvalued.
Does MAUNA KEA TECHNOLOGIES pay dividends?
MAUNA KEA TECHNOLOGIES does not currently pay dividends.
What is MAUNA KEA TECHNOLOGIES’s EPS estimate?
MAUNA KEA TECHNOLOGIES’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does MAUNA KEA TECHNOLOGIES have?
MAUNA KEA TECHNOLOGIES has 195,260,220 shares outstanding.
What happened to MAUNA KEA TECHNOLOGIES’s price movement after its last earnings report?
MAUNA KEA TECHNOLOGIES reported an EPS of -€0.026 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of MAUNA KEA TECHNOLOGIES?
Currently, no hedge funds are holding shares in GB:0P5I
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
MAUNA KEA TECHNOLOGIES
Mauna Kea Technologies SA operates as a medical device enterprise, producing and distributing its offerings throughout Europe and worldwide. Its product line serves various medical specialties such as gastroenterology, pulmonology, and urology. Central to its portfolio is Cellvizio, an in vivo cellular imaging platform that delivers real-time data. This innovative system assists medical practitioners in tracking disease evolution, evaluating immediate physiological responses, delineating ambiguous tissue areas, and providing guidance during surgical procedures. Founded in 2000, the company's headquarters are situated in Paris, France.
Technical Analysis
Theraclion SA
―
Novacyt
―
Eurobio-Scientific SA
―
Ikonisys SA
―
Median Technologies
―